Jove
Visualize
Contact Us

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

284
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
284
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

469
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
469
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

133
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
133
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

98
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
98
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiology at the Threshold of a New Biological Era: The Role of Multiomics and Metabolomics.

Kardiologiia·2026
Same author

Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction.

Kardiologiia·2026
Same authorSame journal

Microcirculatory Features of the Conjunctiva and Retina in Patients with Stable Ischemic Heart Disease and Various Patterns of Coronary Artery Involvement.

Kardiologiia·2026
Same author

Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group.

Kardiologiia·2026
Same author

Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists, and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiovasculatoxicity in Antitumor Therapy". Part II. Primary Prevention of Cardiovasculatoxicity: a Strategy for Protecting the Myocardium and Vessels.

Kardiologiia·2025
Same author

The Influence of Tumor-Associated Systemic Inflammation on Vascular Remodeling in Oncohematological Patients Before Antitumor Therapy.

Kardiologiia·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 2, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

332

[Biomarkers in Heart Failure: Current and Future].

M V Kozhevnikova1, Yu N Belenkov1

  • 1I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow.

Kardiologiia
|June 11, 2021
PubMed
Summary

Diagnosing heart failure (HF) remains challenging, especially in specific patient groups. This study reviews current natriuretic peptide (NUP) use and explores promising novel biomarkers for improved HF diagnosis and personalized treatment.

More Related Videos

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.3K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.4K

Related Experiment Videos

Last Updated: Nov 2, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

332
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.3K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.4K

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Translational Medicine

Background:

  • Heart failure (HF) is a major cause of cardiovascular disease mortality and hospitalization.
  • Current diagnostic methods, including instrumental techniques and biomarkers like natriuretic peptides (NUP), have limitations, particularly for HF with preserved ejection fraction and chronic HF prediction.
  • Existing NUP understanding has evolved, necessitating new biomarkers for improved HF insight and personalized treatment strategies.

Purpose of the Study:

  • To review recent advancements in natriuretic peptides (NUP) for heart failure (HF) diagnosis and management.
  • To discuss novel and promising biomarkers for enhancing HF diagnosis, prognosis, and personalized treatment.
  • To explore the potential clinical utility of emerging biomarkers in understanding HF pathogenesis.

Main Methods:

  • Literature review of recent reports on natriuretic peptides (NUP) in heart failure (HF).
  • Analysis of current research on novel biomarkers for HF diagnosis and phenotyping.
  • Discussion of transcriptomic, proteomic, and metabolomic analyses for biomarker identification in HF.

Main Results:

  • Natriuretic peptides (NUP) are established biomarkers but their limitations highlight the need for new diagnostic tools.
  • Emerging biomarkers identified through omics technologies show promise for improving HF detection and patient stratification.
  • Personalized phenotyping through novel biomarkers could lead to more tailored HF treatment strategies.

Conclusions:

  • Current diagnostic approaches for heart failure (HF) require enhancement, particularly for specific patient subgroups.
  • Novel biomarkers, alongside updated understanding of natriuretic peptides (NUP), are crucial for advancing HF care.
  • Further research into novel biomarkers holds significant potential for personalized medicine in heart failure management.